Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians.
BACKGROUND
Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) represent the leading causes of death in systemic sclerosis (SSc). Screening for these complications has assumed greater importance, but is not universal. The aim of this study is to determine the self-reported screening, diagnosis and treatment practices of rheumatologists and respiratory physicians for SSc-related lung disease.


METHODS
Email survey of 270 rheumatologists and 600 respiratory physicians.


RESULTS
Responses were received from 42 (16%) rheumatologists and 68 (11%) respiratory physicians. Of SSc patients seen by rheumatologists, 17% had ILD and 7.5% had a diagnosis of PAH compared with 31% and 21% for respiratory physicians. Forty per cent of all physicians screened asymptomatic SSc patients without a known diagnosis of ILD or PAH less than annually or not at all. The most commonly used screening investigations were pulmonary function tests (PFT) (95%) and transthoracic echocardiogram (TTE) (78%). In suspected ILD, both groups used high-resolution computed tomography scans and PFT in >90% of patients. In suspected PAH, both used TTE and PFT (>90%); right heart catheterisation was used by only 50% of physicians. In treatment of ILD, rheumatologists used intravenous (IV) cyclophosphamide more often (CYC) (59% vs 28%, P= 0.003) and more respiratory physicians used oral CYC (44% vs 28%, P= 0.012). In PAH, more respiratory physicians used warfarin (68% vs 40%, P= 0.006). Only approximately 65% of physicians had used specific PAH therapy, which may reflect lack of access to a designated PAH treatment centre.


CONCLUSIONS
The heterogeneity of responses revealed in this study raises the importance of screening, diagnosis and treatment algorithms in the management of this potentially life-threatening disease.
Mangat
P
P
Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia.
Conron
M
M
Gabbay
E
E
Proudman
S M
SM
D003520:Cyclophosphamide / Q000627:therapeutic use; D003625:Data Collection / Q000379:methods; D003937:Diagnosis, Differential; D019468:Disease Management; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D017563:Lung Diseases, Interstitial / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D008403:Mass Screening / Q000379:methods; D010820:Physicians; D012120:Respiration Disorders / Q000175:diagnosis / Q000188:drug therapy; D012219:Rheumatology / Q000379:methods*; D012595:Scleroderma, Systemic / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use
D014859:Warfarin; D003520:Cyclophosphamide